![Timber Pharmaceuticals, Inc. logo](/logos/TMBR.webp)
Timber Pharmaceuticals, Inc.
AMEX:TMBR
Overview | Financials
Company Name | Timber Pharmaceuticals, Inc. |
Symbol | TMBR |
Currency | USD |
Price | 1.461 |
Market Cap | 5,014,890 |
Dividend Yield | 0% |
52-week-range | 1.2 - 3.39 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. John Koconis M.B.A. |
Website | https://www.timberpharma.com |
An error occurred while fetching data.
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD